Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Reviewed by Emily Henderson, B.Sc.Jul 27 2020

Announcing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients.

Related Stories

  • Early detection of cancer four years before conventional diagnosis using non-invasive blood test
  • Simple urine test could speed up adrenal cancer diagnosis
  • Study finds viable drug target for triple negative breast cancer

Taxanes represented by paclitaxel and targeted therapy including trastuzumab are two common agents for human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients.

Effectiveness, however, usually comes at the cost of many side effects, some of which are even fatal. Drug-induced interstitial lung diseases (DILDs) comprise a group of drug-induced pulmonary injuries usually caused by using these medications. For DILDs, systemic therapy can be harmful to lung tissues and rapidly threaten the lives of some breast cancer patients.

Through case studies, and reference to related studies in medical databases, the authors discuss how multi-disciplinary integration of clinical practice and pharmacological mechanisms can make anti-cancer agents less harmful, and reduce the incidence of DILD in breast cancer patients during systemic therapy.

Source

Leave a Reply

Your email address will not be published. Required fields are marked *